TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism
Background Transforming growth factor-β (TGFβ) is emerging as a promising target for cancer therapy, given its ability to promote progression of advanced tumors and to suppress anti-tumor immune responses. However, TGFβ also plays multiple roles in normal tissues, particularly during organogenesis,...
Egile Nagusiak: | Canè, S, Van Snick, J, Uyttenhove, C, Pilotte, L, Van den Eynde, BJ |
---|---|
Formatua: | Journal article |
Hizkuntza: | English |
Argitaratua: |
BMJ Publishing Group
2021
|
Antzeko izenburuak
-
TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism
nork: Stefania Canè, et al.
Argitaratua: (2021-02-01) -
Constitutive IDO1 expression in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune resistance
nork: Hennequart, M, et al.
Argitaratua: (2017) -
Constitutive IDO1 expression in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune resistance.
nork: Hennequart, M, et al.
Argitaratua: (2017) -
Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer
nork: Aditi Gupta, et al.
Argitaratua: (2021-11-01) -
TGF-β Neutralization Enhances AngII-Induced Aortic Rupture and Aneurysm in Both Thoracic and Abdominal Regions.
nork: Xiaofeng Chen, et al.
Argitaratua: (2016-01-01)